Literature DB >> 23886617

Emergence and spread of carbapenem-resistant Acinetobacter baumannii sequence type 191 in a Korean hospital.

Mamata Gurung1, Jae Su Rho, Yoo Chul Lee, Hyung Sun Kim, Sun Young Moon, Byung Hyuk Yu, Joo Hyung Lee, Cheol Woo Jang, Seung Yeon Chung, Il Hwan Cho, Hyeon Sook Jee, Seung Won Choi, Ji Young Heo, Je Chul Lee.   

Abstract

Emergence and spread of specific carbapenem-resistant Acinetobacter baumannii (CRAB) clones cause a serious therapeutic problem. This study was aimed to investigate the clonal diversity and genetic basis of antimicrobial resistance among the 69 CRAB isolates from 2009 to 2010 in a Korean hospital. All CRAB isolates were found to be sequence type (ST) 2 using the Institute Pasteur's multilocus sequence typing (MLST) scheme, but classified into two sequence groups and nine pulsotypes. Fifty-six CRAB isolates belonging to two main pulsotypes were found to be ST191 using the Bartual's MLST scheme. All CRAB isolates showed an extensively drug-resistant phenotype. The blaOXA-51/blaOXA-23, blaAmpC/blaPER-1 and armA genes were largely responsible for resistance to carbapenems, extended-spectrum β-lactams and aminoglycosides, respectively. The first CRAB strains identified in 2005 in this hospital were found to be ST2 using the Institute Pasteur's MLST scheme, but showed ST353 using the Bartual's MLST scheme and different pulsotypes from the CRAB isolates from 2009 to 2010. In conclusion, this is the first report of emergence and spread of A. baumannii ST191 in Korea, as well of the genetic basis of its antimicrobial resistance.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carbapenem; Clonal spread; Extended-spectrum β-lactamase; Multi-drug resistance; Sequence type

Mesh:

Substances:

Year:  2013        PMID: 23886617     DOI: 10.1016/j.meegid.2013.07.016

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  7 in total

1.  Molecular Methods for Identification of Acinetobacter Species by Partial Sequencing of the rpoB and 16S rRNA Genes.

Authors:  Azar Dokht Khosravi; Parisa Sadeghi; Abdolrazagh Hashemi Shahraki; Parvin Heidarieh; Nasrin Sheikhi
Journal:  J Clin Diagn Res       Date:  2015-07-01

2.  Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia.

Authors:  Hyo-Ju Son; Eun Been Cho; Moonsuk Bae; Seung Cheol Lee; Heungsup Sung; Mi-Na Kim; Jiwon Jung; Min Jae Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim; Yong Pil Chong
Journal:  Open Forum Infect Dis       Date:  2020-08-24       Impact factor: 3.835

3.  A multi-center study on the risk factors of infection caused by multi-drug resistant Acinetobacter baumannii.

Authors:  Huiping Huang; Borong Chen; Gang Liu; Jing Ran; Xianyu Lian; Xinhua Huang; Nan Wang; Zhengjie Huang
Journal:  BMC Infect Dis       Date:  2018-01-05       Impact factor: 3.090

4.  Small protein A and phospholipase D immunization serves a protective role in a mouse pneumonia model of Acinetobacter baumannii infection.

Authors:  Haitao Li; Hongyi Tan; Yongbin Hu; Pinhua Pan; Xiaoli Su; Chengpin Hu
Journal:  Mol Med Rep       Date:  2017-06-06       Impact factor: 2.952

5.  Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii.

Authors:  Mohammad Hamidian; Steven J Nigro
Journal:  Microb Genom       Date:  2019-10

6.  Whole-genome sequencing for the characterization of resistance mechanisms and epidemiology of colistin-resistant Acinetobacter baumannii.

Authors:  Chorong Hahm; Hae-Sun Chung; Miae Lee
Journal:  PLoS One       Date:  2022-03-04       Impact factor: 3.240

7.  Abrupt Increase in Rate of Imipenem Resistance in Acinetobacter baumannii Complex Strains Isolated from General Hospitals in Korea and Correlation With Carbapenem Administration During 2002-2013.

Authors:  Young Ah Kim; Yoon Soo Park; Taemi Youk; Hyukmin Lee; Kyungwon Lee
Journal:  Ann Lab Med       Date:  2018-03       Impact factor: 3.464

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.